Perpetual Ltd’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.36M | Buy |
21,294
+1,425
| +7% | +$307K | 0.08% | 132 |
|
|
2026
Q1 | $4.32M | Buy |
19,869
+3,247
| +20% | +$720K | 0.07% | 124 |
|
|
2025
Q4 | $3.8M | Buy |
16,622
+3,409
| +26% | +$777K | 0.05% | 139 |
|
|
2025
Q3 | $3.06M | Buy |
13,213
+1,997
| +18% | +$407K | 0.04% | 163 |
|
|
2025
Q2 | $2.08M | Sell |
11,216
-8,171
| -42% | -$1.52M | 0.02% | 193 |
|
|
2025
Q1 | $4.06M | Sell |
19,387
-56
| -0.3% | -$10.9K | 0.05% | 149 |
|
|
2024
Q4 | $3.46M | Sell |
19,443
-63
| -0.3% | -$11.6K | 0.04% | 155 |
|
|
2024
Q3 | $3.85M | Sell |
19,506
-218
| -1% | -$40.7K | 0.04% | 154 |
|
|
2024
Q2 | $3.38M | Buy |
19,724
+751
| +4% | +$124K | 0.04% | 176 |
|
|
2024
Q1 | $3.45M | Sell |
18,973
-3,112
| -14% | -$536K | 0.03% | 179 |
|
|
2023
Q4 | $3.42M | Buy |
22,085
+1,593
| +8% | +$232K | 0.04% | 168 |
|
|
2023
Q3 | $3.05M | Buy |
20,492
+3,592
| +21% | +$527K | 0.03% | 187 |
|
|
2023
Q2 | $2.28M | Hold |
16,900
| – | – | 0.02% | 226 |
|
|
2023
Q1 | $2.69M | Buy |
+16,900
| New | +$2.58M | 0.02% | 220 |
|
|
2020
Q3 | $2.42M | Hold |
27,600
| – | – | 0.17% | 153 |
|
|
2020
Q2 | $2.71M | Buy |
+27,600
| New | +$2.43M | 0.25% | 102 |
|
|
2020
Q1 | – | Sell |
-27,600
| Closed | -$2.44M | – | 163 |
|
|
2019
Q4 | $2.44M | Hold |
27,600
| – | – | 0.36% | 52 |
|
|
2019
Q3 | $2.09M | Buy |
27,600
+3,700
| +15% | +$254K | 0.32% | 56 |
|
|
2019
Q2 | $1.74M | Buy |
+23,900
| New | +$1.88M | 0.28% | 56 |
|
|
2018
Q3 | – | Sell |
-12,155
| Closed | -$1.13M | – | 180 |
|
|
2018
Q2 | $1.13M | Sell |
12,155
-4,800
| -28% | -$469K | 0.14% | 75 |
|
|
2018
Q1 | $1.6M | Hold |
16,955
| – | – | 0.22% | 58 |
|
|
2017
Q4 | $1.66M | Sell |
16,955
-4,300
| -20% | -$405K | 0.21% | 65 |
|
|
2017
Q3 | $1.94M | Hold |
21,255
| – | – | 0.27% | 58 |
|
|
2017
Q2 | $1.54M | Sell |
21,255
-2,900
| -12% | -$195K | 0.12% | 154 |
|
|
2017
Q1 | $1.57M | Buy |
24,155
+4,000
| +20% | +$251K | 0.16% | 100 |
|
|
2016
Q4 | $1.26M | Buy |
20,155
+3,300
| +20% | +$201K | 0.19% | 68 |
|
|
2016
Q3 | $1.06M | Sell |
16,855
-27,557
| -62% | -$1.78M | 0.09% | 160 |
|
|
2016
Q2 | $2.75M | Sell |
44,412
-1,800
| -4% | -$110K | 0.27% | 93 |
|
|
2016
Q1 | $2.64M | Buy |
46,212
+1,300
| +3% | +$72.5K | 0.27% | 90 |
|
|
2015
Q4 | $2.66M | Buy |
44,912
+8,500
| +23% | +$490K | 0.3% | 84 |
|
|
2015
Q3 | $1.98M | Hold |
36,412
| – | – | 0.24% | 90 |
|
|
2015
Q2 | $2.45M | Buy |
36,412
+3,900
| +12% | +$255K | 0.28% | 84 |
|
|
2015
Q1 | $1.9M | Hold |
32,512
| – | – | 0.21% | 95 |
|
|
2014
Q4 | $2.13M | Buy |
32,512
+1,200
| +4% | +$75.7K | 0.25% | 121 |
|
|
2014
Q3 | $1.81M | Sell |
31,312
-4,000
| -11% | -$222K | 0.2% | 122 |
|
|
2014
Q2 | $1.99M | Buy |
35,312
+4,000
| +13% | +$210K | 0.18% | 106 |
|
|
2014
Q1 | $1.61M | Sell |
31,312
-1,000
| -3% | -$50.5K | 0.24% | 96 |
|
|
2013
Q4 | $1.71M | Buy |
32,312
+1,000
| +3% | +$49.1K | 0.22% | 93 |
|
|
2013
Q3 | $1.4M | Sell |
31,312
-2,000
| -6% | -$88.7K | 0.2% | 107 |
|
|
2013
Q2 | $1.38M | Buy |
+33,312
| New | +$1.46M | 0.21% | 103 |
|
Other funds holding ABBV
ATO
Perpetual Ltd's ABBV Position: Q2 2026 in Review
Perpetual Ltd increased its AbbVie (ABBV) stake by 7.2% in Q2 2026, buying an estimated $307K and bringing the position to 21,294 shares worth $5.36M. The position accounts for 0.08% of the portfolio, ranked #132.
Perpetual Ltd first reported a position in ABBV in Q2 2013 and has held it in 40 quarters since. 1,758 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Perpetual Ltd held 21,294 shares of AbbVie worth $5.36M as of Q2 2026.
- Perpetual Ltd bought 1,425 AbbVie shares in Q2 2026, an estimated $307K.
- AbbVie made up 0.08% of Perpetual Ltd's portfolio in Q2 2026, its #132 holding.
- Perpetual Ltd first reported a position in AbbVie in Q2 2013 and has held it in 40 quarters since.
- 1,758 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Perpetual Ltd's 13F filing for Q2 2026, filed 15 Jul 2026.